NorthSea Therapeutics completes US$80m Ser...Dutch metabolic disease specialist NorthSea Therapeutics NV has baged US$80m in a Series C fundraising co-led by Ysios Capital and Forbion Growth. more ➔
Depixus raises €30.6m in Series A financ...French-British magnetic trap specialist Depixus has raised €30,6m to develop a commercial instrument based on the companys MAGNA technology. more ➔
Ichnos Sciences in licence deal with Almir...Ichnos Sciences Inc. has licenced the gobal rights on its IL-1RAP antagonistic antibody ISB 880 to Almirall SA for the treatment of autoimmune disorders. more ➔
Vifor Pharma Ltd to be acquired for CHF10....Biologicals and vaccine specialist CSL Ltd is set to acquire Swiss Vifor Pharma Ltd for CHF10.9bn. more ➔
Apogenix gets €25.8m cash injection for...German Apogenix AG has received a €26m in funding for a pivotal Phase III study of its CD95 ligand blocker asunercept for the treatment of COVID-19 patients. more ➔
British Adendra Therapeutics closes $53m f...The 2021 spin out of London-based Francis Crick Institute is the very first UK company formation deal of life sciences investor ATP (Apple Tree Partners). more ➔
Recordati bags EUSA to strengthen rare dis...Italian pharma company Recordati is putting €750m on the table to acquire UK-based specialty pharmaceutical company EUSA Pharma. more ➔
Sanofi acquires therapeutic acne vaccineSanofi is strengthening its vaccine business by acquiring an Austrian company. The French pharma group is taking over skin disease specialist Origrimm Biotechnology. more ➔
US-Greek Venture gets €32m cash injectio...US cell & gene therapy manufacturer Orgenesis Inc. announced that its joint venture with Theracell Advanced Biotechnology SA has received €32m in funding by Enterprise Greece. more ➔
Early-stage ventures fighting AMR wanted!The start-up competition @AMR conference supported by INCATE has started. Early-stage ventures fighting drug resistant bacterial infections in the therapeutics or diagnostics area interested to be on … more ➔